Rare Diseases Strategy

Debate between Philip Dunne and Ben Howlett

Tuesday 28th March 2017 Westminster Hall

[Mr Dunne]

The right hon. Gentleman anticipates something that I will come to shortly in my speech, but we acknowledge that challenge and we recognise that there will continue to be concerns among patient groups and Members. I hope that my hon. Friend the Member for Bath in particular will understand that the proposed changes are intended to put in place a fairer, more transparent framework for the evaluation of technologies for very rare diseases as they are developed.

I want to respond specifically to the challenge posed by my hon. Friend and the shadow Minister on the real need to ensure that the commitments set out in the UK rare disease strategy are fully realised. It is right that last week in the House, my hon. Friend the Under-Secretary of State for Public Health and Innovation made a personal commitment to that effect in her response to my hon. Friend’s oral question, and I am happy to reiterate that commitment today. I can confirm to the House that I have agreed with the chief executive of NHS England that by the end of this year he will deliver an implementation plan for those of the 51 commitments of the UK strategy for rare diseases for which NHS England has lead responsibility. For those commitments that fall outside NHS England’s remit, the Department will work collaboratively across stakeholders to contribute to the implementation plan. I am sure my hon. Friend will agree that the development of that plan will be a significant step in the journey.

[Ben Howlett]

indicated assent.

[Mr Dunne]

I welcome my hon. Friend’s acknowledgement of that. We are absolutely clear that we need to ensure that the proposals are used to drive real action and make tangible improvements for patients affected by rare diseases. It is not only about having a plan but about ensuring that the plan has effect for sufferers of these conditions. That is why we have recently reconfigured and strengthened the governance arrangements and formed a more streamlined UK rare disease policy board to monitor and co-ordinate progress in implementing the strategy.

In addition, we have strengthened the patient voice with the appointment of two patient representatives to the policy board. To make our work more transparent, a broad online stakeholder forum will operate in collaboration with the policy board to allow a more meaningful dialogue with the rare disease community. The rare disease policy board will be supported by clearly defined task and finish groups to examine progress objectively and to consider in particular the diagnostic odyssey that my hon. Friend referred to, which can be so frustrating for those who are still unable to determine their condition. That issue is a considerable worry for anyone affected by a rare disease, who will be familiar with the problem.

I will conclude slightly ahead of schedule by confirming that the lives of patients with rare diseases can be improved only by means of concerted and co-ordinated action. I take this opportunity to reaffirm the Government’s aims to drive real improvements in the care and treatment of those affected by rare diseases by working with stakeholders to deliver the standard of care and treatment that all patients deserve and to ensure that the implementation plan for England is delivered by the end of this year.

Oral Answers to Questions

Debate between Philip Dunne and Ben Howlett

Monday 18th April 2016 Commons Chamber

[Mr Dunne]

The right hon. Gentleman, who speaks with some knowledge on these matters, has given a strong indication to the House that there will be a broad measure of support, which we thoroughly welcome. I will offer the Prime Minister his advice.

[Ben Howlett (Bath) (Con)]

Two weeks ago I had the great privilege of visiting Rolls-Royce up the road in Bristol, where I met apprentices and workers at the defence aerospace operations and turbine manufacturing facility. I witnessed the important work that Rolls-Royce is doing around the country on manufacturing nuclear engines for servicing naval vessels. Does the Minister agree that Trident stands to benefit the economy by virtue of the many jobs it will create?

Defence

Debate between Philip Dunne and Ben Howlett

Wednesday 2nd March 2016 Ministerial Corrections

[Ben Howlett (Bath) (Con)]

Given that Ministry of Defence procurement operates under European law, what assessment has the Minister made of a potential exit from the European Union on UK SMEs that rely on MOD contracts?

[Mr Dunne]

As my hon. Friend knows, the UK defence and security industry is the largest in Europe. As the default position, we continue to place contracts on the basis of open competition. EU procurement directives apply to our procurement, which means that EU contractors are eligible to compete for our contracts in the same way as UK and other international companies, other than when we declare an article 346 exemption for warlike stores, which accounts for about 45% of our procurement.

[Official Report, 29 February 2016, Vol. 606, c. 662.]

Letter of correction from Mr Dunne:

An error has been identified in the response I gave to my hon. Friend the Member for Bath (Ben Howlett) during Questions to the Secretary of State for Defence.

The correct response should have been:

Oral Answers to Questions

Debate between Philip Dunne and Ben Howlett

Monday 29th February 2016 Commons Chamber

[Mr Dunne]

My hon. Friend speaks magnificently not only for his constituents, but for the largest UK defence contractor, whose main centre of engineering innovation is in his constituency. I congratulate him on that and applaud him for it.

[Ben Howlett (Bath) (Con)]

Given that Ministry of Defence procurement operates under European law, what assessment has the Minister made of a potential exit from the European Union on UK SMEs that rely on MOD contracts?

[Mr Dunne]

As my hon. Friend knows, the UK defence and security industry is the largest in Europe. As the default position, we continue to place contracts on the basis of open competition. EU procurement directives apply to our procurement, which means that EU contractors are eligible to compete for our contracts in the same way as UK and other international companies, other than when we declare an article 346 exemption for warlike stores, which accounts for about 45% of our procurement.[Official Report, 2 March 2016, Vol. 606, c. 5MC.]